1
|
Fu HJ, Zhou H, Tang Y, Li J, Zhang D, Ding SY, Huang QW, Wang C. Tai Chi and other mind-body interventions for cancer-related fatigue: an updated systematic review and network meta-analyses protocol. BMJ Open 2022; 12:e052137. [PMID: 34996789 PMCID: PMC8744122 DOI: 10.1136/bmjopen-2021-052137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION Fatigue is one of the most common symptoms in patients with cancer and is responsible for a reduced quality of life. There is a strong evidence base for mind-body interventions (MBIs) to manage cancer-related fatigue (CRF). However, the efficacy of Tai Chi and other MBIs in the treatment of CRF remains controversial. METHODS AND ANALYSIS We will perform a systematic review and network meta-analyses (NMAs) that aim to assess the effects of Tai Chi and other MBIs in patients with CRF. The following databases will be searched from their inception to 1 August 2021: PubMed, EMBASE, Scopus, OVID, Web of Science, Cochrane Central Register of Controlled Trials, the China National Knowledge Infrastructure, China Science and Technology Journal Database, Chinese Biomedical Database and Wan Fang Digital Journals. We will include randomised controlled trials that compare MBIs with no treatment, placebo and usual care in the treatment of CRF. The primary outcome will be changes in the fatigue state as evaluated by validated scales. We will perform a Bayesian NMA to analyse all the evidence for each outcome. The surface under the cumulative ranking curve and the mean ranks will be used to rank the various treatments. We will assess the quality of evidence contributing to network estimates of outcomes using the Grading of Recommendations Assessment, Development and Evaluation system framework. ETHICS AND DISSEMINATION This NMAs will be disseminated through publication in a peer-reviewed journal. Since no individual patient data will be involved in the review, ethics approval and concerns about privacy are not needed. PROSPERO REGISTRATION NUMBER CRD42021244999.
Collapse
Affiliation(s)
- Hong-Juan Fu
- Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine Shierqiao Campus, Chengdu, China
- Sichuan Integrative Medicine Hospital, Chengdu, China
| | - Hao Zhou
- Sichuan Integrative Medicine Hospital, Chengdu, China
| | - Yong Tang
- Acupuncture-Moxibustion School, Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu, China
| | - Jie Li
- Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine Shierqiao Campus, Chengdu, China
| | - Da Zhang
- Sichuan Integrative Medicine Hospital, Chengdu, China
| | - Song-Yi Ding
- Sichuan Integrative Medicine Hospital, Chengdu, China
| | - Qin-Wan Huang
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Chao Wang
- Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine Shierqiao Campus, Chengdu, China
- Sichuan Integrative Medicine Hospital, Chengdu, China
| |
Collapse
|
2
|
Qin YY, Li RF, Wu GF, Zhu Z, Liu J, Zhou CZ, Guan WJ, Luo JY, Yu XX, Ou YM, Jiang M, Zhong NS, Luo YM. Effect of tiotropium on neural respiratory drive during exercise in severe COPD. Pulm Pharmacol Ther 2015; 30:51-6. [DOI: 10.1016/j.pupt.2014.11.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Revised: 11/17/2014] [Accepted: 11/21/2014] [Indexed: 12/01/2022]
|
3
|
Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin 2014; 30:1427-36. [PMID: 24666181 DOI: 10.1185/03007995.2014.908828] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Poor adherence to treatment may contribute to the treatment gap in chronic obstructive pulmonary diseases (COPD). The aim of the current study was to describe the association between adherence to treatment and the risk of COPD moderate (ME) and severe (SE) exacerbations, and health care utilization. RESEARCH DESIGN AND METHODS Observational single cohort study utilizing the Quebec Provincial Health Insurance databases. All patients older than 40 years with a diagnosis of COPD between 2001 and 2010 were entered in the study cohort at the time of their first prescription for tiotropium (TIO) alone or co-administered with fluticasone propionate/salmeterol (TIO + FSC). Follow-up continued to the last known claim or death. Adherence was measured by the medication possession ratio (MPR) ≥80% and persistence defined as no treatment gap ≥30 days. MAIN OUTCOME MEASURES ME was defined as use of an oral corticosteroid or antibiotic, SE as COPD related hospitalization or an emergency room (ER) visit. COPD related health care resource utilization ascertained was prescription of rescue medications, ER visits, hospitalizations, intensive care unit (ICU) admissions, intubations, and general practitioner (GP) and respirologist visits. RESULTS There were 23,707 patients included in this study. Compliance and persistence with TIO for monotherapy patients were 61.1% and 47.6% respectively. For patients treated with TIO + FSC, compliance and persistence for TIO were 62.9% and 45.3% respectively, and for FSC they were 35.4% and 33.0%. Multivariate analyses showed a significant (P < 0.001) adjusted odds ratios for ME (OR(ME)) and SE (OR(SE)) for TIO compliant vs. non-compliant patients (TIO: OR(ME) = 0.543, OR(SE) = 0.712; TIO + FSC: OR(ME) = 0.436, OR(SE) = 0.570). Similarly for FSC compliance: OR(ME) = 0.546; OR(SE) = 0.749. Similar results were observed for persistence. Compliance and persistence with TIO and FSC were associated with significantly reduced rates of health care utilization. CONCLUSIONS Despite the typical limitations of an administrative database study, the results of this large population-based study have shown that reduced adherence to treatment with TIO and FSC is associated with increased risk for exacerbations and higher health care utilization in COPD patients.
Collapse
Affiliation(s)
- A Ismaila
- Medical Affairs, GlaxoSmithKline , Mississauga, ON , Canada
| | | | | | | | | | | | | |
Collapse
|
4
|
Laforest L, Licaj I, Devouassoux G, Hartwig S, Marvalin S, Van Ganse E. Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. Chron Respir Dis 2012; 10:11-8. [DOI: 10.1177/1479972312464245] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Tiotropium is an innovative intervention in chronic obstructive pulmonary disease (COPD). Early adherence to tiotropium remains inadequately explored, notably time from initiation to discontinuation (persistence). In patients with COPD, the factors associated with the risk of discontinuing the treatment with tiotropium within 12 months following initiation were identified (12-month persistence). Claim databases from the French Social Security were used. A random sample of patients (aged 50–80 years) who initiated tiotropium soon after launch was selected. Factors associated with the persistence were investigated (Log-rank test and multivariate Cox model). Of the 1147 newly treated patients (mean age 68 years, 33% women), 64% remained in the treatment of tiotropium for over a period of 12 months following initiation. More than 10% of the patients interrupted therapy after a single dispensing, most often those with mild COPD. Lower risks of discontinuing tiotropium within 12 months following initiation were observed when it was initiated by a private sector specialist (hazard ratio (HR) = 0.65, 95% confidence interval (CI) = (0.52–0.82)), by hospital-based physician (HR = 0.58, 95% CI = (0.42–0.78)), when ≥ 2 other respiratory drugs were associated (HR = 0.74, 95% CI = (0.58–0.95)) and in case of long-term disease status (HR = 0.78, 95% CI = (0.63–0.97)). Conversely, no clear effect appeared according to age or gender. In this population of patients with COPD, fewer early discontinuations of tiotropium were observed in patients having a severe condition.
Collapse
Affiliation(s)
- Laurent Laforest
- Unité de Pharmacoépidémiologie, CHU-Lyon, d’Odontologie - UMR 5558 CNRS - Université Claude Bernard Lyon, France
| | - Idlir Licaj
- Unité de Pharmacoépidémiologie, CHU-Lyon, d’Odontologie - UMR 5558 CNRS - Université Claude Bernard Lyon, France
| | - Gilles Devouassoux
- Service de pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Susanne Hartwig
- Unité de Pharmacoépidémiologie, CHU-Lyon, d’Odontologie - UMR 5558 CNRS - Université Claude Bernard Lyon, France
| | - Serge Marvalin
- Direction Régionale du Service Médical Rhône-Alpes, 26, rue d'Aubigny, Lyon, France
| | - Eric Van Ganse
- Unité de Pharmacoépidémiologie, CHU-Lyon, d’Odontologie - UMR 5558 CNRS - Université Claude Bernard Lyon, France
- Service de pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
5
|
Wang T, Luo G, Hu Y, Li F, Ma J, Wang J, Zuo P, Xiong W, Liu X, Zhao J, Xiong S, Zhang Z, Li C, Zhao S, Sun J, Xu Y. Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease. ACTA ACUST UNITED AC 2011; 31:614. [DOI: 10.1007/s11596-011-0570-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2011] [Indexed: 11/24/2022]
|
6
|
La Piana GE, Corda L, Bertella E, Montemurro LT, Pini L, Tantucci C. Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD. Int J Chron Obstruct Pulmon Dis 2011; 6:399-405. [PMID: 21857779 PMCID: PMC3157942 DOI: 10.2147/copd.s22179] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Use of short-acting β(2)-agonists in chronic obstructive pulmonary disease (COPD) during treatment with long-acting β(2)-agonists is recommended as needed, but its effectiveness is unclear. The purpose of this study was to assess the additional bronchodilating effect of increasing doses of salbutamol during acute and chronic treatment with formoterol in patients with COPD. METHODS Ten patients with COPD underwent a dose-response curve to salbutamol (until 800 μg of cumulative dose) after a 1-week washout (baseline), 8 hours after the first administration of formoterol 12 μg (day 1), and after a 12-week and 24-week period of treatment with formoterol (12 μg twice daily by dry powder inhaler). Peak expiratory flow, forced expiratory volume in one second (FEV(1)), forced vital capacity, and inspiratory capacity were measured at the different periods of treatment and at different steps of the dose-response curve. RESULTS Despite acute or chronic administration of formoterol, maximal values of peak expiratory flow, FEV(1), and forced vital capacity after 800 μg of salbutamol were unchanged compared with baseline. The baseline FEV(1) dose-response curve was steeper than that at day 1, week 12, or week 24 (P < 0.0001). Within each dose-response curve, FEV(1) was different only at baseline and at day 1 (P < 0.001), when FEV(1) was still greater at 800 μg than at 0 μg (P < 0.02). In contrast, the forced vital capacity dose-response curves were similar at the different periods, while within each dose-response curve, forced vital capacity was different in all instances (P < 0.001), always being higher at 800 μg than at 0 μg (P < 0.05). CONCLUSION In patients with stable COPD, the maximal effect of salbutamol on peak expiratory flow, FEV(1), and forced vital capacity was unchanged after either acute or chronic treatment with formoterol. With increasing doses of salbutamol, FEV(1) increased only after acute administration of formoterol. Forced vital capacity also significantly improved during long-term treatment with formoterol.
Collapse
Affiliation(s)
| | - Luciano Corda
- Prima Divisione di Medicina Interna, Spedali Civili, Brescia, Italy
| | - Enrica Bertella
- Cattedra di Malattie dell’Apparato Respiratorio, Università di Brescia
| | | | - Laura Pini
- Cattedra di Malattie dell’Apparato Respiratorio, Università di Brescia
| | - Claudio Tantucci
- Cattedra di Malattie dell’Apparato Respiratorio, Università di Brescia
| |
Collapse
|
7
|
Chitano P. Models to understand contractile function in the airways. Pulm Pharmacol Ther 2011; 24:444-51. [PMID: 21511049 DOI: 10.1016/j.pupt.2011.04.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Revised: 04/04/2011] [Accepted: 04/07/2011] [Indexed: 11/25/2022]
Abstract
Although the role of contractile function in the airways is controversial, there is general consensus on the importance of airway smooth muscle (ASM) as a therapeutic target for diseases characterized by airway obstruction, such as asthma or chronic obstructive pulmonary disease. Indeed, the use of bronchodilators to relax ASM is the most common and effective practice to treat airflow obstruction. Excessive pathologic bronchoconstriction may originate from primary alterations of ASM mechanical function and/or from the effects exerted on ASM function by disease processes, such as inflammation and remodeling. An in depth knowledge of the potentially multiple mechanisms that distinctively regulate primary and secondary alterations in ASM contractile function would be essential for the development of new therapeutic approaches aimed at preventing the occurrence or reducing the severity of bronchoconstriction. The present review discusses studies that have addressed the mechanisms of altered ASM contractile function in models of airway hyperresponsiveness. Although not comprehensively, in the present review, animal models of intrinsic airway hyperresponsiveness, normal ontogenesis, and allergic sensitization are analyzed in the attempt to summarize the current knowledge on regulatory mechanisms of ASM contractile function in health and disease. Studies in human ASM and the need for additional models to understand contractile function in the airways are also discussed.
Collapse
Affiliation(s)
- Pasquale Chitano
- Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
| |
Collapse
|
8
|
Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010; 9:783-92. [DOI: 10.1517/14740338.2010.500611] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJG. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010; 104:995-1004. [PMID: 20303247 DOI: 10.1016/j.rmed.2010.02.017] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2009] [Revised: 02/11/2010] [Accepted: 02/21/2010] [Indexed: 11/17/2022]
Abstract
BACKGROUND Clinical information on 24-h spirometric efficacy of combining tiotropium and salmeterol compared to single-agent therapy is lacking in patients with COPD. METHODS A randomized, double-blind, four-way crossover study of 6-week treatment periods comparing combination therapy of tiotropium 18 microg plus qd or bid salmeterol 50 microg versus single-agent therapy. Serial 24-h spirometry (FEV(1), FVC), effects on dyspnea (TDI focal score) and rescue salbutamol use were evaluated in 95 patients. RESULTS Tiotropium plus qd salmeterol was superior to tiotropium or salmeterol alone in average FEV(1) (0-24h) by 72 mL and 97 mL (p<0.0001), respectively. Compared to this qd regimen, combination therapy including bid salmeterol provided comparable daytime (0-12h: 12 mL, p=0.38) bronchodilator effects, but significantly more bronchodilation during the night-time (12-24h: 73 mL, p<0.0001). Clinically relevant improvements in TDI focal score were achieved with bronchodilator combinations including salmeterol qd or bid (2.56 and 2.71; p<0.005 versus components). Symptom benefit of combination therapies was also reflected in less need for reliever medication. All treatments were well tolerated. CONCLUSION Compared to single-agent therapy, combination therapy of tiotropium plus salmeterol in COPD provided clinically meaningful improvements in airflow obstruction and dyspnea as well as a reduction in reliever medication.
Collapse
Affiliation(s)
- J A van Noord
- Department of Respiratory Diseases, Atrium medisch centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
10
|
Lodewijckx C, Sermeus W, Vanhaecht K, Panella M, Deneckere S, Leigheb F, Decramer M. Inhospital management of COPD exacerbations: a systematic review of the literature with regard to adherence to international guidelines. J Eval Clin Pract 2009; 15:1101-10. [PMID: 20367712 DOI: 10.1111/j.1365-2753.2009.01305.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Rationale Chronic obstructive pulmonary disease (COPD) exacerbations are a leading cause of hospitalization. Suboptimal inhospital management is expected to lead to more frequent exacerbations and recurrent hospital admission, and is associated with increased mortality. Aims To explore inhospital management of COPD and to compare the results with recommendations from international guidelines. Methods A literature search was carried out for relevant articles published 2000-2009 in the databases Medline, Cochrane Library, Cumulative Index for Nursing and Allied Health Literature and Invert. In addition, the reference lists of the selected articles were examined. Main inclusion criteria were as follows: COPD, exacerbation, hospitalization, description of inpatient management, and clinical trials. Assessment and treatment strategies in different studies were analysed and compared with American Thoracic Society-European Respiratory Society and Global Initiative for Chronic Obstructive Lung Disease guidelines. Outcomes were analysed. Results Seven eligible studies were selected. Non-pharmacological treatment was infrequently explored. When compared with international guidelines, diagnostic assessment and therapy were suboptimal, especially non-pharmacological treatment. Respiratory physicians were more likely to perform recommended interventions than non-respiratory physicians. Conclusions Adherence to international guidelines is low for inhospital management of COPD exacerbations, especially in terms of non-pharmacological treatment. Further investigation is recommended to explore strategies like care pathways that improve performance of recommended interventions.
Collapse
|
11
|
Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374:695-703. [PMID: 19716961 DOI: 10.1016/s0140-6736(09)61252-6] [Citation(s) in RCA: 394] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. METHODS In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 microg or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1 s (FEV(1)). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, number NCT00313209 for M2-127, and NCT00424268 for M2-128. FINDINGS In the salmeterol plus roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium plus roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean prebronchodilator FEV(1) by 49 mL (p<0.0001) in patients treated with salmeterol, and 80 mL (p<0.0001) in those treated with tiotropium. Similar improvement in postbronchodilator FEV(1) was noted in both groups. Furthermore, roflumilast had beneficial effects on other lung function measurements and on selected patient-reported outcomes in both groups. Nausea, diarrhoea, weight loss, and, to a lesser extent, headache were more frequent in patients in the roflumilast groups. These adverse events were associated with increased patient withdrawal. INTERPRETATION Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients. FUNDING Nycomed.
Collapse
|
12
|
Okapo SO, Gupta J, Martinez E, Mark R. In vitro deposition properties of nebulized formoterol fumarate: effect of nebulization time, airflow, volume of fill and nebulizer type. Curr Med Res Opin 2009; 25:807-16. [PMID: 19207092 DOI: 10.1185/03007990802708236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The aim of this study was to investigate in vitro the delivery of a new long-acting beta2-agonist (LABA) drug formoterol fumarate inhalation solution (20 microg/2 mL) nebulized with and without ipratropium bromide (0.5 mg/2.5 mL) at different administration times (2.5-22.5 min), airflows (5-28.3 L/min), nebulizer fill volumes (2-6 mL),and nebulizer brands (Pari LC+, Ventstream and DeVilbiss). METHOD Formoterol fumarate with and without ipratropium bromide was aerosolized at different administration times, airflows, nebulizer fill volumes, and nebulizer brands. The drug deposited on the throat, filter and stage plates was collected and analyzed by HPLC to determine the aerodynamic profiles of the nebulized drugs under each variable. RESULTS In addition to altering the aerosol characteristics,increasing the nebulizer fill volume including the addition of ipratropium bromide produced a significant(p50.05) increase in the drug output. As expected, sputtering time was significantly longer at low airflows, and vice versa at higher airflows but with a significant loss of drug delivered presumably due to greater solvent evaporation at higher airflows. Airflows between 10 and 28.3 L/min and a nebulization time of approximately 10 min appear sufficient for producing aerosols within the respirable range (1-5 mm MMAD) with the nebulizer/compressor combination used.While the drug output varied significantly (p50.05) among the three brands of nebulizers tested, the LC+ nebulizer appears to produce aerosols (2.7 0.1 microm MMAD) capable of penetrating more deeply into the lung than the other nebulizers evaluated under the current test conditions. This study did not attempt to evaluate different nebulizer/compressor combinations. Also, the cascade impaction data may not necessarily reflect aerosol deposition in the airways in vivo, which may be different depending on the health status of the patient. CONCLUSION The results demonstrated that administration of nebulized formoterol fumarate require proper selection of a delivery system/method for safe and effective therapy of the medication with and without ipratropium bromide.
Collapse
Affiliation(s)
- Samuel O Okapo
- Department of Analytical Development, Dey LP, 2751 Napa Valley Corporate Drive, Napa, CA 4558, USA.
| | | | | | | |
Collapse
|
13
|
Price D, Sharma A, Cerasoli F. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opin Drug Metab Toxicol 2009; 5:417-24. [DOI: 10.1517/17425250902828337] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|